Cumberland Pharmaceuticals Inc's Comment on Supply Chain
The company holds agreements with multiple manufacturers for Caldolor supplies, sourcing commercial products from three manufacturers in 2025. For Kristalose, it has agreements with an international supplier for the active pharmaceutical ingredient (API) and a packager for finished product supplies in 2025. The Sancuso supply agreement was assigned to the company following an acquisition, with production relocated to a new FDA-approved facility in 2022, supplying products in 2023 and 2024. Vaprisol supply includes raw material inventory acquired and a 2020 agreement with a new manufacturer; manufacturing was transferred in 2021 but is pending FDA approval due to regulatory issues, with a special compounded supply provided in the interim. Vibativ supply was acquired with multi-year inventory; manufacturing was transferred to a new FDA-approved supplier, with a new smaller package launched in 2024 and continued supply planned for 2025. U.S. product distribution is exclusively managed by Cardinal Health Specialty Solutions in 2025, overseeing logistics, warehousing, and shipping to pharmaceutical wholesalers serving hospitals, clinics, and retail pharmacies.
Cumberland Pharmaceuticals Inc's Comment on Supply Chain
The company holds agreements with multiple manufacturers for Caldolor supplies, sourcing commercial products from three manufacturers in 2025. For Kristalose, it has agreements with an international supplier for the active pharmaceutical ingredient (API) and a packager for finished product supplies in 2025. The Sancuso supply agreement was assigned to the company following an acquisition, with production relocated to a new FDA-approved facility in 2022, supplying products in 2023 and 2024. Vaprisol supply includes raw material inventory acquired and a 2020 agreement with a new manufacturer; manufacturing was transferred in 2021 but is pending FDA approval due to regulatory issues, with a special compounded supply provided in the interim. Vibativ supply was acquired with multi-year inventory; manufacturing was transferred to a new FDA-approved supplier, with a new smaller package launched in 2024 and continued supply planned for 2025. U.S. product distribution is exclusively managed by Cardinal Health Specialty Solutions in 2025, overseeing logistics, warehousing, and shipping to pharmaceutical wholesalers serving hospitals, clinics, and retail pharmacies.
Sources:
Cumberland Pharmaceuticals Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Cumberland Pharmaceuticals Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
